Alnylam Pharmaceuticals Inc(ALNY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | NDX | P/E | 38.44 | EPS (ttm) | 5.92 | Insider Own | 0.32% | Shs Outstand | 133.7M | Perf Week | -2.41% |
| Market Cap | 30.46B | Forward P/E | 23.62 | EPS next Y | 48.47% | Insider Trans | -1.29% | Shs Float | 133.4M | Perf Month | -11.06% |
| Enterprise Value | 30.14B | PEG | 0.33 | EPS next Q | 1.66 | Inst Own | 100.61% | Short Float | 5.78% | Perf Quarter | -21.06% |
| Income | 0.81B | P/S | 6.34 | EPS this Y | 178.56% | Inst Trans | -1.11% | Short Ratio | 4.44 | Perf Half Y | -26.21% |
| Sales | 4.80B | P/B | 22.48 | EPS next 5Y | 72.24% | ROA | 15.96% | Short Interest | 7.71M | Perf YTD | -42.75% |
| Book/sh | 10.13 | P/C | 9.21 | EPS past 3/5Y | - | ROE | 100.7% | 52W High | -53.09% ($485.36) | Perf Year | -50.87% |
| Cash/sh | 24.72 | P/FCF | 38.37 | Sales past 3/5Y | 52.98% 49.77% | ROIC | 20.01% | 52W Low | 15.09% ($197.81) | Perf 3Y | 46.25% |
| Dividend Est. | - | EV/EBITDA | 28.58 | EPS Y/Y TTM | 347.31% | Gross Margin | 79.65% | Volatility(W/M) | 3.31% 3.74% | Perf 5Y | 15.15% |
| Dividend TTM | - | EV/Sales | 6.27 | Sales Y/Y TTM | 95.14% | Oper. Margin | 20.81% | ATR (14) | 8.55 | Perf 10Y | 513.8% |
| Dividend Ex-Date | - | Quick Ratio | 2.99 | EPS Q/Q | 337.86% | Profit Margin | 16.82% | RSI (14) | 45.27 | Recom | 1.61 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.05 | Sales Q/Q | 66.86% | SMA20 | -0.72% ($229.31) | Beta | 0.38 | Target Price | $370.42 |
| Payout | - | Debt/Eq | 2.21 | Earnings | 2026/10/29 | SMA50 | -4.76% ($239.04) | Rel Volume | 0.83 | Prev Close | $224.03 |
| Employees | 2500 | LT Debt/Eq | 1.98 | EPS/Sales Surpr. | -25.78% -2.36% | SMA200 | -21.23% ($289.02) | Avg Volume(3M) | 1.74M | Price | $227.66 |
| IPO | 2004/5/28 | Option/Short | Yes/Yes | Trades | 22693 | Volume | 1,437,000 | Change | 1.62% |
🧬 A leading biotech company in RNAi (RNA interference)-based drug development. Founded in 2002 in Cambridge, Massachusetts, the company is headquartered in the United States and operates an RNAi therapeutics pipeline targeting rare genetic disorders, cardiovascular, central nervous system, and liver diseases. It stands as a flagship company within a leading biotech group in the RNAi therapeutics space.
Over the past 1 year, on the lower side
53% below its 1-year high.
Traded about as much as usual. That is 83% of its average volume.
Next earnings report: October 29
2 days to go.
ALNY makes money exceptionally well
Of every $100 in sales, $20.81 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +178.6% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $3,844. Peers typically go for $3,449. Compared with its own 1-year average, it is 50% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be +15.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 100.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #7 of 594 in the industry
Based on market cap of $30B.
ONC#6 BeOne Medicines Ltd ADR $39B PER 65.2 
ALNY#7 Alnylam Pharmaceuticals Inc $30B PER 38.4 
RPRX#8 Royalty Pharma plc $29B PER 34.5 
GMAB#9 Genmab ADR $27B PER 35.4 
ROIV#10 Roivant Sciences Ltd $26B PER - 
FAQ
What kind of company is ALNY?
ALNY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ALNY?
The market cap of ALNY is approximately $30.5B, ranking 448 within its sector.
What is the P/E ratio of ALNY?
ALNY has a P/E ratio of approximately 38.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ALNY?
ALNY has recorded a 52-week high of $485.36 and a low of $197.81.
